Literature DB >> 12865351

Adenovirus-mediated expression of human prorelaxin promotes the invasive potential of canine mammary cancer cells.

Josh D Silvertown1, Brad J Geddes, Alastair J S Summerlee.   

Abstract

This study reports the characterization of a recombinant adenoviral vector containing a tetracycline-regulatable promoter, driving the bicistronic expression of the human H2 preprorelaxin (hH2) cDNA and enhanced green fluorescent protein, via an internal ribosomal entry site. An hH2 ELISA was used to measure the secreted levels of recombinant hH2 in transfected canine (CF33.Mt) and human (MDA-MB-435) mammary cancer cell lines over a 6-d period; secreted peptide peaked on d 2 and 4 for the canine and human cell types, respectively. An unprocessed hH2 immunoreactive form of approximately 18 kDa was identified by Western blotting analysis and confirmed by mass spectrometry, suggesting that prorelaxin remains unprocessed in these cell types. The biological activity of the adenovirally expressed human prorelaxin was measured in the established human monocytic cell line THP-1 cAMP ELISA and in an in vitro Transwell cell migration system. Exogenous recombinant hH2 and adenovirally-mediated delivery of prorelaxin to CF33.Mt cells conferred a significant migratory action in the cells, compared with controls. Cell proliferation assays were performed to discount the possibility that the effect of relaxin was mitogenic. Thus, we have demonstrated that prorelaxin has the ability to facilitate cell migration processes exclusive of its ability to stimulate cell proliferation. In validating this adenovirus-based system, we have created a potential tool for further exploration of the physiology of relaxin in mammalian systems.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12865351     DOI: 10.1210/en.2003-0248

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  11 in total

Review 1.  Regulatable gene expression systems for gene therapy applications: progress and future challenges.

Authors:  S Goverdhana; M Puntel; W Xiong; J M Zirger; C Barcia; J F Curtin; E B Soffer; S Mondkar; G D King; J Hu; S A Sciascia; M Candolfi; D S Greengold; P R Lowenstein; M G Castro
Journal:  Mol Ther       Date:  2005-08       Impact factor: 11.454

Review 2.  Regulatable gene expression systems for gene therapy.

Authors:  Nuria Vilaboa; Richard Voellmy
Journal:  Curr Gene Ther       Date:  2006-08       Impact factor: 4.391

3.  Relaxin enhances the oncogenic potential of human thyroid carcinoma cells.

Authors:  Sabine Hombach-Klonisch; Joanna Bialek; Bogusz Trojanowicz; Ekkehard Weber; Hans-Jürgen Holzhausen; Josh D Silvertown; Alastair J Summerlee; Henning Dralle; Cuong Hoang-Vu; Thomas Klonisch
Journal:  Am J Pathol       Date:  2006-08       Impact factor: 4.307

4.  Controlled extracellular matrix degradation in breast cancer tumors improves therapy by trastuzumab.

Authors:  Ines Beyer; Zongyi Li; Jonas Persson; Ying Liu; Ruan van Rensburg; Roma Yumul; Xiao-Bing Zhang; Mien-Chie Hung; André Lieber
Journal:  Mol Ther       Date:  2010-11-16       Impact factor: 11.454

5.  RGD peptide-modified adenovirus expressing hepatocyte growth factor and X-linked inhibitor of apoptosis improves islet transplantation.

Authors:  Hao Wu; A-Rum Yoon; Feng Li; Chae-Ok Yun; Ram I Mahato
Journal:  J Gene Med       Date:  2011-12       Impact factor: 4.565

6.  Elevated serum levels of human relaxin-2 in patients with esophageal squamous cell carcinoma.

Authors:  Peng Ren; Zhen-Tao Yu; Li Xiu; Mei Wang; Hua-Min Liu
Journal:  World J Gastroenterol       Date:  2013-04-21       Impact factor: 5.742

7.  Bipartite vector encoding hVEGF and hIL-1Ra for ex vivo transduction into human islets.

Authors:  Ravikiran Panakanti; Ram I Mahato
Journal:  Mol Pharm       Date:  2009 Jan-Feb       Impact factor: 4.939

8.  Role of relaxin-2 in human primary osteosarcoma.

Authors:  Jinfeng Ma; Min Niu; Wenjiu Yang; Lina Zang; Yongming Xi
Journal:  Cancer Cell Int       Date:  2013-06-10       Impact factor: 5.722

Review 9.  Biology of primate relaxin: a paracrine signal in early pregnancy?

Authors:  Eric S Hayes
Journal:  Reprod Biol Endocrinol       Date:  2004-06-16       Impact factor: 5.211

10.  Relaxin reduces xenograft tumour growth of human MDA-MB-231 breast cancer cells.

Authors:  Yvonne Radestock; Cuong Hoang-Vu; Sabine Hombach-Klonisch
Journal:  Breast Cancer Res       Date:  2008-08-21       Impact factor: 6.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.